Indeed, a recent study using LRRK2 antisense oligonucleotides (ASOs) has shown that decreased endogenous levels of LRRK2 reduces α-synuclein inclusion in order to be a potential therapeutic strategy for preventing PD [251]. Here, SNCA is linked to Parkinson disease.